Highlights and key learnings from 15 years of the TREAT-NMD Advisory Committee for Therapeutics (TACT)

Topic:

Pre-Clinical Research

Poster Number: P298

Author(s):

Laura Robertson, TREAT-NMD Services Ltd, Cathy Turner, Newcastle University, JWMDRC, David Allison, TREAT-NMD Services Limited, Katie Bushby, Newcastle University, JWMDRC, Cristina Csimma, PhD, Sardona Therapeutics, Annamaria De Luca, PhD, University of Bari, Dipartimento di Farmacia, Emma Heslop, Newcastle University, JWMDRC, Dominic Wells, PhD, Royal Veterinary College, Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, Volker Straub, PhD, Newcastle University, JWMDRC

The TREAT-NMD Advisory Committee for Therapeutics (TACT) has been providing advice to pharma and academic groups on their neuromuscular disease therapy development pipelines since 2009. _x000D_
The model is unique and well established with over 80 bespoke, expert and independent review panels being brought together so far. Patients or patient representatives are always part of those panels._x000D_
Feedback shows that TACT has generated recommendations that have greatly helped investigators, including industry, in evaluating their potential compounds and therapy development programmes. It has encouraged applicants to consider these in a methodical fashion with clear go/no-go decisions and with optimal use of funding and resources.